血浆簇集蛋白clusterin水平与AD严重度相关

2011-04-15 MedSci原创 MedSci原创

MedSci提示:最近几年有关clusterin与AD研究比较热,但是屡有相反的观点出现。值得中国学者立即跟进进行研究!  荷兰一项研究表明,血浆簇集蛋白(clusterin)水平与阿尔茨海默病(AD)的基线患病率及严重程度显著相关,但与AD的发病率无关。论文发表于《美国医学会杂志》[JAMA 2011,305(13):1354]。   研究者检测了60例AD患者的基线血浆簇集蛋白浓

MedSci提示:最近几年有关clusterin与AD研究比较热,但是屡有相反的观点出现。值得中国学者立即跟进进行研究!

 荷兰一项研究表明,血浆簇集蛋白(clusterin)水平与阿尔茨海默病(AD)的基线患病率及严重程度显著相关,但与AD的发病率无关。论文发表于《美国医学会杂志》[JAMA 2011,305(13):1354]。

  研究者检测了60例AD患者的基线血浆簇集蛋白浓度,以及随机子队列926例参试者和随访过程中156例新发AD患者的血浆簇集蛋白浓度。

  结果为,AD的患病率随血浆簇集蛋白浓度升高而增高[经校正年龄、性别、载脂蛋白E状况、糖尿病、吸烟、冠心病和高血压等因素后,血浆簇集蛋白每增加一个标准差(SD)的比值比(OR)=1.63]。经简易精神状态检查(MMSE)量表评估显示,在AD患者中,簇集蛋白水平与疾病的严重程度呈正相关(当血浆簇集蛋白每增加一个SD时,MMSE评分的校正后差异=-1.36,P = 0.047)。

  随访期间未发现血浆簇集蛋白浓度与AD发病率相关 (P=0.77)。

原始出处:

Schrijvers E, et al "Plasma clusterin and the risk of Alzheimer disease" JAMA 2011; 305: 1333-26.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634119, encodeId=127d16341199a, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sun Feb 12 18:08:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783260, encodeId=71d61e832608c, content=<a href='/topic/show?id=adc148e929' target=_blank style='color:#2F92EE;'>#cluster#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4879, encryptionId=adc148e929, topicName=cluster)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 14 05:08:00 CST 2011, time=2011-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055169, encodeId=678620551697f, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sun Oct 02 11:08:00 CST 2011, time=2011-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634119, encodeId=127d16341199a, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sun Feb 12 18:08:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783260, encodeId=71d61e832608c, content=<a href='/topic/show?id=adc148e929' target=_blank style='color:#2F92EE;'>#cluster#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4879, encryptionId=adc148e929, topicName=cluster)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 14 05:08:00 CST 2011, time=2011-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055169, encodeId=678620551697f, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sun Oct 02 11:08:00 CST 2011, time=2011-10-02, status=1, ipAttribution=)]
    2011-08-14 gracezdd
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634119, encodeId=127d16341199a, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Sun Feb 12 18:08:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783260, encodeId=71d61e832608c, content=<a href='/topic/show?id=adc148e929' target=_blank style='color:#2F92EE;'>#cluster#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4879, encryptionId=adc148e929, topicName=cluster)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 14 05:08:00 CST 2011, time=2011-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055169, encodeId=678620551697f, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sun Oct 02 11:08:00 CST 2011, time=2011-10-02, status=1, ipAttribution=)]